Gedeon Richter drug boasts better schizophrenia impact than aripiprazole

10 October 2018

Hungary's largest drugmaker Gedeon Richter (RICHT: HB) has presented more findings from its cariprazine studies in schizophrenia.

The presentations at the congress of European College of Neuropsychopharmacology have been billed as confirmation of the hypothesis that negative and cognitive symptoms of schizophrenia can be improved by a compound with dopamine D3 effect in vivo and with balanced occupancy at dopamine D3 and D2 receptors.

Cariprazine, which is a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, showed significantly better improvement in the negative symptoms of schizophrenia compared to the widely used antipsychotic, aripiprazole, and also compared to placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK